Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study
International Journal of Urology · 2026
DOI: 10.1111/iju.70523 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuki Endo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nippon Medical School Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aimed to evaluate the clinical relevance of early relative dose intensity (eRDI) during enfortumab vedotin (EV) monotherapy in patients with metastatic urothelial carcinoma (mUC) based on a Japanese real‐world multicenter cohort.
Methods
We retrospectively analyzed 119 patients with mUC who received EV. The temporal trend of total relative dose intensity (tRDI), defined as the cumulative relative dose intensity during treatment, was assessed over the first 5 months. eRDI, calculated as the mean RDI over the initial 3 months, was also evaluated. Survival analyses were performed in 84 patients evaluable beyond the first radiographic assessment, excluding those with early progressive disease (PD). Patients were stratified by eRDI (≥ 80% vs. < 80%), and progression‐free survival (PFS) and overall survival (OS) were compared. Subgroup analyses were conducted according to the presence or absence of adverse event–related dose modification (AE‐related DM).
Results
Dose intensity gradually declined during the early treatment phase. The eRDI was not significantly associated with PFS or OS in the PD‐excluded cohort ( n = 84). However, among patients without AE‐related DM ( n = 44), high eRDI was associated with significantly longer PFS (median 11.7 vs. 4.2 months; p = 0.001) and OS (not reached vs. 13.8 months; p = 0.021). No significant association was observed between eRDI and survival in patients with AE‐related DM.
Conclusions
Although eRDI was not an overall significant prognostic factor, it showed clinical relevance in patients without AE‐related DM. These findings underscore the importance of preserving eRDI in patients with sufficient tolerability and support individualized dosing strategies for EV therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
- Division of Urology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Uro-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
- Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
- Department of Urology, Iwate Medical University School of Medicine, Iwate, Japan.
ORCID-Profile: Yuki Endo, Yuma Sakura, Nozomi Hayakawa, Ryo Yamashita, Suguru Shirotake, Wataru Obara, Eiji Kikuchi
Zitieren
APA
Endo, Y., Sakura, Y., Kaneko, G., Hayakawa, N., Ikarashi, D., Yamashita, R., Shirotake, S., Obara, W., Kondo, Y., & Kikuchi, E. (2026). Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study. International Journal of Urology. https://doi.org/10.1111/iju.70523
Vancouver
Endo Y, Sakura Y, Kaneko G, Hayakawa N, Ikarashi D, Yamashita R, et al. Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study. International Journal of Urology. 2026. doi:10.1111/iju.70523
BibTeX
@article{Endo2026,
author = {Endo, Yuki and Sakura, Yuma and Kaneko, Go and Hayakawa, Nozomi and Ikarashi, Daiki and Yamashita, Ryo and Shirotake, Suguru and Obara, Wataru and Kondo, Yukihiro and Kikuchi, Eiji},
title = {Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real‐World Multicenter Study},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70523}
}
EUVIMED